Tessa L Holyoake

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2686052/publications.pdf

Version: 2024-02-01

210 papers	14,817 citations	28274 55 h-index	19190 118 g-index
216 all docs	216 docs citations	216 times ranked	19670 citing authors

#	Article	IF	Citations
1	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	12.8	43
2	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 2020, 34, 1613-1625.	7.2	46
3	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 2019, 33, 981-994.	7.2	99
4	hsa-mir183/EGR1â€“mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 2018, 131, 1532-1544.	1.4	40
5	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine, 2018, 24, 450-462.	30.7	123
6	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Journal of the National Cancer Institute, 2018, 110, 467-478.	6.3	76
7	Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. Blood Cells, Molecules, and Diseases, 2018, 69, 119-122.	1.4	5
8	The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood, 2017, 129, 1595-1606.	1.4	240
9	Preclinical approaches in chronic myeloid leukemia: from cells to systems. Experimental Hematology, 2017, 47, 13-23.	0.4	24
10	CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 2017, 129, 199-208.	1.4	58
11	Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 2017, 23, 1234-1240.	30.7	382
12	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type Î³ in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2017, 10, 129.	17.0	17
13	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	7.0	38
14	Validating a network hub in leukaemia stem cells. Oncoscience, 2017, 4, 3-4.	2.2	0
15	Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitorâ€“treated CML stem cells. Blood, 2016, 128, 2671-2682.	1.4	89
16	ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy, 2016, 12, 936-948.	9.1	84
17	Adult hematopoietic stem cells lacking Hif-1Î± self-renew normally. Blood, 2016, 127, 2841-2846.	1.4	67
18	Casting a NETwork instead of shooting magic bullets. Cell Cycle, 2016, 15, 3147-3148.	2.6	0

#	Article	IF	Citations
19	Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. Cancer Discovery, 2016, 6, 1248-1257.	9.4	120
20	Lifting the Differentiation Embargo. Cell, 2016, 167, 45-46.	28.9	4
21	CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 2016, 128, 371-383.	1.4	61
22	Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 2016, 6, 25476.	3.3	66
23	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature, 2016, 534, 341-346.	27.8	204
24	Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 2016, 30, 823-832.	7.2	29
25	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clinical Cancer Research, 2016, 22, 2051-2061.	7.0	52
26	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2016, 128, 3057-3057.	1.4	1
27	Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival. Blood, 2016, 128, 932-932.	1.4	2
28	Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 2016, 7, 51651-51664.	1.8	12
29	Hif-1Î± and Hif-2Î± synergize to suppress AML development but are dispensable for disease maintenance. Journal of Experimental Medicine, 2015, 212, 2223-2234.	8.5	65
30	Repositioned to kill stem cells. Nature, 2015, 525, 328-329.	27.8	4
31	Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nature Protocols, 2015, 10, 149-168.	12.0	21
32	Do we need more drugs for chronic myeloid leukemia?. Immunological Reviews, 2015, 263, 106-123.	6.0	37
33	Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. Blood, 2015, 126, 4024-4024.	1.4	7
34	Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences. Blood, 2015, 126, 4021-4021.	1.4	0
35	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. Blood, 2015, 126, 1569-1569.	1.4	0
36	Dual Glutathione-S-Transferase-Î¸1 and -Î¼1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. Clinical Pharmacology and Therapeutics, 2014, 96, 694-703.	4.7	13

#	Article	IF	Citations
37	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. European Journal of Clinical Investigation, 2014, 44, 1239-1245.	3.4	51
38	Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting. Stem Cells, 2014, 32, 1373-1379.	3.2	27
39	The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors. Stem Cells, 2014, 32, 2324-2337.	3.2	83
40	Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis, 2014, 3, e90-e90.	4.9	18
41	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood, 2014, 123, 3951-3962.	1.4	189
42	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood, 2014, 124, 1492-1501.	1.4	134
43	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 2014, 124, 3847-3862.	8.2	53
44	Cytomegalovirus Infection Is Associated with Expansions of CD8 T Cells and Highly Oligoclonal Vdelta1 Gamma/Delta T Cells in Patients Treated with Dasatinib for Chronic Myelogenous Leukaemia. Blood, 2014, 124, 1814-1814.	1.4	1
45	Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. Blood, 2014, 124, 517-517.	1.4	18
46	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. Blood, 2014, 124, 4512-4512.	1.4	1
47	Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients. Blood, 2014, 124, 4357-4357.	1.4	0
48	Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives. Blood, 2014, 124, 4508-4508.	1.4	0
49	Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood, 2013, 121, 4175-4183.	1.4	105
50	Quantitative proteomics analysis of <scp>BMS</scp>â€214662 effects on <scp>CD</scp>34 positive cells from chronic myeloid leukaemia patients. Proteomics, 2013, 13, 153-168.	2.2	6
51	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wntâ€"Î²-catenin signaling. Blood, 2013, 121, 1824-1838.	1.4	234
52	Targeting survival pathways in chronic myeloid leukaemia stem cells. British Journal of Pharmacology, 2013, 169, 1693-1707.	5.4	64
53	A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Leukemia, 2013, 27, 932-940.	7.2	23
54	Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 2013, 98, 1335-1343.	3.5	54

#	Article	IF	Citations
55	Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1â€“BCR-ABLâ€“JAK2 Complex. Journal of the National Cancer Institute, 2013, 105, 405-423.	6.3	71
56	A Specific PTPRC/CD45 Phosphorylation Event Governed by Stem Cell Chemokine CXCL12 Regulates Primitive Hematopoietic Cell Motility. Molecular and Cellular Proteomics, 2013, 12, 3319-3329.	3.8	18
57	Safety and efficacy of pulsed imatinib with or without <scp>G</scp>â€<scp>CSF </scp>versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5Âyears followâ€up. British Journal of Haematology, 2013, 163, 674-676.	2.5	8
58	The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood, 2013, 121, 628-637.	1.4	66
59	Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 2013, 121, 2542-2552.	1.4	87
60	Hif-2Î± is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood, 2013, 122, 1741-1745.	1.4	75
61	Autocrine TNF-Î± production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 2013, 122, 3335-3339.	1.4	81
62	Redirecting traffic using the XPO1 police. Blood, 2013, 122, 2926-2928.	1.4	13
63	Role of autophagy in cancer prevention, development and therapy. Essays in Biochemistry, 2013, 55, 133-151.	4.7	33
64	Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy. Current Cancer Drug Targets, 2013, 13, 724-734.	1.6	32
65	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. Journal of Clinical Investigation, 2013, 123, 4144-4157.	8.2	192
66	Inhibition Of Microenvironmental Interleukin-1 Signaling Enhances TKI-Mediated Targeting Of Chronic Myelogenous Leukemia Stem Cells. Blood, 2013, 122, 512-512.	1.4	1
67	Targeting autophagy potentiates tyrosine kinase inhibitorâ€“induced cell death in Philadelphia chromosomeâ€“positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2013, 123, 3634-3634.	8.2	2
68	p53 and c-Myc Are Critical Signaling Hubs That Maintain Chronic Myeloid Leukemia. Blood, 2013, 122, 1465-1465.	1.4	0
69	HIF-1Î± Is Not Essential For The Establishment Of MLL-Leukaemic Stem Cells. Blood, 2013, 122, 3767-3767.	1.4	3
70	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. Blood, 2013, 122, 1469-1469.	1.4	0
71	Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor. Blood, 2013, 122, 2710-2710.	1.4	0
72	Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia, 2012, 26, 1555-1563.	7.2	33

#	Article	IF	Citations
73	Expression of p89c-Mybex9b, an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells. Blood Cancer Journal, 2012, 2, e71-e71.	6.2	11
74	Rac2-MRC-cIIIâ€“generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 2012, 119, 4253-4263.	1.4	147
75	Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 2012, 48, 199-201.	1.4	5
76	Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 2012, 12, 381-392.	2.4	15
77	Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 2012, 120, 4441-4443.	1.4	21
78	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
79	Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 2012, 26, 545-547.	1.7	2
80	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 2012, 119, 1501-1510.	1.4	359
81	Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell, 2012, 21, 266-281.	16.8	374
82	Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia. Cancer Cell, 2012, 21, 577-592.	16.8	317
83	<scp>BCR</scp>â€<scp>ABL</scp>1 tyrosine kinase sustained <scp>MECOM</scp> expression in chronic myeloid leukaemia. British Journal of Haematology, 2012, 157, 446-456.	2.5	9
84	Lineage Tracing of Pf4-Cre Marks Hematopoietic Stem Cells and Their Progeny. PLoS ONE, 2012, 7, e51361.	2.5	63
85	Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML. Blood, 2012, 120, 1664-1664.	1.4	1
86	Microenvironmental Protection of CML Stem and Progenitor Cells From Tyrosine Kinase Inhibitors Through N-Cadherin and Wnt Signaling. Blood, 2012, 120, 912-912.	1.4	1
87	Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.. Blood, 2012, 120, 2776-2776.	1.4	1
88	Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America, 2011, 25, 951-966.	2.2	23
89	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 2011, 96, 590-601.	3.5	17
90	Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 2011, 118, 2035-2043.	1.4	106

#	Article	IF	Citations
91	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica, 2011, 96, 1779-1782.	3.5	20
92	Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 2011, 155, 128-130.	2.5	7
93	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell, 2011, 19, 740-753.	16.8	124
94	In Search of CML Stem Cellsâ€™ Deadly Weakness. Current Hematologic Malignancy Reports, 2011, 6, 82-87.	2.3	21
95	Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?. Expert Review of Hematology, 2011, 4, 369-371.	2.2	9
96	Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 2011, 208, 2155-2158.	8.5	25
97	Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro. PLoS ONE, 2011, 6, e19164.	2.5	39
98	Leukemia-Induced Alterations in Bone Marrow Cytokine and Chemokine Levels Contribute to Altered Stem Cell Lodgment and Impairment of Normal Stem Cell Growth in CML. Blood, 2011, 118, 962-962.	1.4	0
99	Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells. Blood, 2011, 118, 2736-2736.	1.4	0
100	Pharmacological Inhibition of the Stress-Related Deacetylase SIRT1 Enhances Eradication of CML stem Cells. Blood, 2011, 118, 448-448.	1.4	0
101	Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 2011, 24, 285-91.	0.2	2
102	Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 2010, 115, 2241-2250.	1.4	51
103	BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood, 2010, 115, 3185-3195.	1.4	85
104	Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 2010, 116, 2112-2121.	1.4	56
105	Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 2010, 95, 224-231.	3.5	112
106	Targeting Chronic Myeloid Leukemia Stem Cells. Current Hematologic Malignancy Reports, 2010, 5, 81-87.	2.3	30
107	Uptake of synthetic Low Density Lipoprotein by leukemic stem cells â€" a potential stem cell targeted drug delivery strategy. Journal of Controlled Release, 2010, 148, 380-387.	9.9	30
108	Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate. Cancer Cell, 2010, 17, 427-442.	16.8	245

#	Article	IF	Citations
109	Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors â€“ A synthesis of clinical and laboratory data. Blood Reviews, 2010, 24, 1-9.	5.7	14
110	Targeted therapy in haematological malignancies. Journal of Pathology, 2010, 220, 404-418.	4.5	29
111	A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 2010, 13, 103-111.	0.3	34
112	Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). British Journal of Haematology, 2010, 149, 65-69.	2.5	30
113	Expression of the Transcriptional Repressor Gfi-1 Is Regulated by C/EBPÎ± and Is Involved in Its Proliferation and Colony Formationâ€“Inhibitory Effects in p210BCR/ABL-Expressing Cells. Cancer Research, 2010, 70, 7949-7959.	0.9	27
114	Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Research, 2010, 38, 6831-6840.	14.5	7
115	Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib. Blood, 2010, 116, 514-514.	1.4	8
116	BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. Blood, 2010, 116, 515-515.	1.4	14
117	Alterations In Wnt Signalling In the Megakaryocytic Lineage Leads to Bone Marrow Failure and Myelofibrosis. Blood, 2010, 116, 628-628.	1.4	5
118	BMS-214662 Eliminates Quiescent and Proliferating Acute Myeloid Leukemia Cells through Activation of Protein Kinase CÎ² and Enhances the Efficacy of Cytosine Arabinoside. Blood, 2010, 116, 2167-2167.	1.4	0
119	Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.. Blood, 2010, 116, 3404-3404.	1.4	2
120	SIRT1 Inhibition Induces Apoptosis In Human CML Progenitors by Enhancing p53 Acetylation and Activation. Blood, 2010, 116, 200-200.	1.4	0
121	Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib. PLoS Computational Biology, 2009, 5, e1000503.	3.2	53
122	Targeting autophagy potentiates tyrosine kinase inhibitorâ€“induced cell death in Philadelphia chromosomeâ€“positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2009, 119, 1109-1123.	8.2	503
123	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 2009, 37, 206-214.	0.4	2
124	Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 2009, 37, 395-401.	0.4	9
125	Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 2009, 37, 692-700.	0.4	31
126	The Chronic Myeloid Leukemia Stem Cell. Clinical Lymphoma and Myeloma, 2009, 9, S376-S381.	1.4	24

#	Article	IF	Citations
127	BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38â^' cells, through activation of protein kinase Cî². Blood, 2009, 114, 4186-4196.	1.4	46
128	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. Blood, 2009, , .	1.4	6
129	Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.. Blood, 2009, 114, 1428-1428.	1.4	15
130	Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.. Blood, 2009, 114, 1724-1724.	1.4	1
131	Foxo Transcription Factor Activity Is Retained in Quiescent Chronic Myeloid Leukaemia Stem Cells and Activated by Tyrosine Kinase Inhibitors to Mediate â€œinduced-quiescenceâ€•in More Mature progenitors.. Blood, 2009, 114, 187-187.	1.4	5
132	Stem Cells in Leukemia and Other Hematological Malignancies. , 2009, , 111-136.		0
133	Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.. Blood, 2009, 114, 190-190.	1.4	0
134	Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.. Blood, 2009, 114, 42-42.	1.4	0
135	Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research, 2008, 68, 9624-9633.	0.9	82
136	Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood, 2008, 111, 2329-2338.	1.4	96
137	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111, 2843-2853.	1.4	117
138	Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood, 2008, 111, 5252-5255.	1.4	15
139	Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.. Blood, 2008, 112, 1070-1070.	1.4	1
140	Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. Blood, 2008, 112, 3205-3205.	1.4	7
141	Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells. Blood, 2008, 112, 4222-4222.	1.4	0
142	Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.. Blood, 2008, 112, 1077-1077.	1.4	0
143	Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro. Blood, 2008, 112, 3227-3227.	1.4	3
144	N-Cadherin-Mediated Microenvironmental Interactions Protect CML Stem Cells from Imatinib Mediated Apoptosis.. Blood, 2008, 112, 1073-1073.	1.4	0

#	Article	IF	Citations
145	HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, 2007, 28, 299-309.	2.8	40
146	Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis. Clinical Cancer Research, 2007, 13, 5048-5055.	7.0	123
147	Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABLâ€“positive leukemias identified by a proteomics approach. Blood, 2007, 109, 1701-1711.	1.4	89
148	Response: Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL. Blood, 2007, 109, 1336-1336.	1.4	12
149	Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 2007, 109, 4016-4019.	1.4	283
150	Stem cells in chronic myeloid leukaemia. Cancer Biomarkers, 2007, 3, 183-191.	1.7	3
151	High loading dose AmBisome(R) is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica, 2007, 92, 572-573.	3.5	4
152	Therapeutic targets in chronic myeloid leukaemia. Hematological Oncology, 2007, 25, 66-75.	1.7	34
153	GATA1 mutational analysis in chronic myeloid leukaemia. British Journal of Haematology, 2007, 137, 375-376.	2.5	0
154	Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells. Stem Cells, 2007, 25, 1853-1861.	3.2	55
155	Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia Sources. Stem Cells, 2007, 25, 3111-3120.	3.2	81
156	The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Molecular Biotechnology, 2007, 36, 81-89.	2.4	33
157	Effective Induction of Apoptosis in Chronic Myeloid Leukemia CD34+ Cells by the Histone Deacetylase Inhibitor LAQ824 in Combination with Imatinib.. Blood, 2007, 110, 1031-1031.	1.4	8
158	A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.. Blood, 2007, 110, 1033-1033.	1.4	2
159	Bortezomib Has Anti-Proliferative and Apoptotic Effects Against CML Stem Cells, Including the Quiescent Population.. Blood, 2007, 110, 2943-2943.	1.4	3
160	Normal Short-Term but Reduced Long-Term Engraftment Capacity of CML Hematopoietic Cells with Skewed Myeloid Lineage Differentiation Is Seen in an Improved Mouse Model of Human Hematopoiesis.. Blood, 2007, 110, 3383-3383.	1.4	1
161	Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.. Blood, 2007, 110, 3378-3378.	1.4	0
162	Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia.. Blood, 2007, 110, 1097-1097.	1.4	0

#	Article	IF	Citations
163	Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. Blood, 2007, 110, 2944-2944.	1.4	0
164	HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.. Blood, 2007, 110, 2641-2641.	1.4	12
165	Reversible Transplantable Chronic Phase CML-Like Disease in SCLtTA/BCR-ABL Transgenic Mice.. Blood, 2007, 110, 1002-1002.	1.4	1
166	A Consensus on Fungal Polymerase Chain Reaction Diagnosis?. Journal of Molecular Diagnostics, 2006, 8, 376-384.	2.8	99
167	Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 2006, 108, 1370-1373.	1.4	152
168	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 2006, 107, 4532-4539.	1.4	590
169	Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate. Clinical Cancer Research, 2006, 12, 626-633.	7.0	86
170	BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.. Blood, 2006, 108, 739-739.	1.4	7
171	Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.. Blood, 2006, 108, 744-744.	1.4	1
172	Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.. Blood, 2006, 108, 1379-1379.	1.4	0
173	The Dual Src/Abl Kinase Inhibitor SKI-606 Effectively Inhibits Bcr-Abl Kinase Activity and Reduces Proliferation of CML Primitive Progenitor Cells.. Blood, 2006, 108, 1370-1370.	1.4	12
174	Punish the parent not the progeny. Blood, 2005, 105, 1862-1866.	1.4	141
175	Can we afford to let sleeping dogs lie?. Blood, 2005, 105, 1840-1841.	1.4	24
176	Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 2005, 128, 578-579.	2.5	14
177	Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 2005, 33, 1140-1146.	0.4	18
178	Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 2005, 103, 210-210.	4.1	15
179	Evolving molecular therapy for chronic myeloid leukaemiaâ€"are we on target?. Hematology, 2005, 10, 349-359.	1.5	38
180	Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.. Blood, 2005, 106, 1997-1997.	1.4	2

#	Article	IF	Citations
181	BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).. Blood, 2005, 106, 693-693.	1.4	5
182	Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro, but Does Not Eradicate Quiescent CML Stem Cells.. Blood, 2005, 106, 695-695.	1.4	3
183	Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.. Blood, 2005, 106, 1125-1125.	1.4	1
184	Published rather than Proposed Definitions for Invasive Fungal Infection Must Be Applied to Allow Standardization in Clinical Trials. Clinical Infectious Diseases, 2004, 38, 1648-1649.	5.8	4
185	Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 2004, 45, 1775-1781.	1.3	51
186	Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro.. Blood, 2004, 104, 1979-1979.	1.4	5
187	Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro.. Blood, 2004, 104, 1997-1997.	1.4	2
188	Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.. Blood, 2004, 104, 716-716.	1.4	0
189	Gene Expression Profiling in Quiescent Stem Cells from Normal and Chronic Myeloid Leukaemia Patients.. Blood, 2004, 104, 2962-2962.	1.4	0
190	The Role of DNA Methylation of HoxA5, a Regulator of Haematopoiesis, in Progression to Myeloid Blast Crisis in CML.. Blood, 2004, 104, 2053-2053.	1.4	0
191	G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro.. Blood, 2004, 104, 2941-2941.	1.4	1
192	Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 2003, 41, 111-131.	1.6	9
193	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 2003, 98, 1776-1777.	4.1	1
194	Mobilization of Ph chromosomeâ€negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylateâ€induced complete cytogenetic remission. British Journal of Haematology, 2003, 123, 479-483.	2.5	21
195	Î±1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 2002, 99, 713-715.	1.4	79
196	BCR-ABL FISH monitoring of CML: a survey of current UK practice. British Journal of Haematology, 2002, 119, 272-273.	2.5	0
197	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002, 99, 319-325.	1.4	1,107
198	Evolution of bone marrow transplantation â€“ the original immunotherapy. Trends in Immunology, 2001, 22, 88-92.	6.8	18

#	Article	IF	Citations
199	Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 2001, 97, 720-728.	1.4	153
200	In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice. British Journal of Haematology, 2001, 114, 49-56.	2.5	9
201	A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. Hematological Oncology, 2001, 19, 89-106.	1.7	16
202	Telomere Length Dynamics in Normal Individuals and in Patients with Hematopoietic Stem Cellâ€Associated Disorders. Annals of the New York Academy of Sciences, 2001, 938, 293-304.	3.8	73
203	Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood, 2000, 95, 1883-1890.	1.4	182
204	The Number of CD34+Cells Mobilized into the Peripheral Blood Can Predict the Quality of Subsequent Collections. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 89-93.	1.8	9
205	Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia. Blood, 1999, 94, 2056-2064.	1.4	487
206	Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia. Blood, 1999, 94, 2056-2064.	1.4	18
207	Prevalence and haemopoietic effects of low serum vitamin B12levels in geriatric medical patients. British Journal of Nutrition, 1997, 78, 57-63.	2.3	23
208	CD34+ Cells Can Be Selected Efficiently from Cryopreserved Peripheral Blood Progenitor Cells and Can Retain Their Proliferative Potential. Stem Cells and Development, 1997, 6, 501-510.	1.0	10
209	Acute Cardiotoxicity After Daunorubicin in Acute Myeloid Leukaemia. Leukemia and Lymphoma, 1991, 3, 305-307.	1.3	1
210	Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. , 0, , 161-190.		0